Please enter exact key words
A First-in-class Antibody Targeting Sphingosine 1-Phosphate Receptor

for the Treatment of Autoimmune Diseases and Inflammatory Diseases

Home / Available Projects / A First-in-class Antibody Targeting Sphingosine 1-Phosphate Receptor
Drug Name GPCR-targeted Project 002

Sphingosine 1-phosphate (S1P) is a member of a class of lipids called sphingolipids that are involved in stimulating angiogenesis and mediating fibrosis. A first-in-class monoclonal antibody targeting sphingosine 1-phosphate receptor 1 (S1PR1) is developed for the treatment of autoimmune diseases such as multiple sclerosis and inflammation.

Target Sphingosine 1-phosphate receptor 1 (S1PR1)
Drug Modality Monoclonal antibody
Indication Autoimmune diseases; Inflammation
Product Category Biologic
Mechanism of Action S1PR1 agonists
Status Discovery
Patent Granted

More Detail Available Upon Request

We look forward to hearing from you.

Our customer service representatives are available 24 hours a day, from Monday to Sunday Online Inquiry

Protheragen's business is growing rapidly after founded in Ronkonkoma, New York. Our business has evolved from the initial intermediary service to encompass segments in equity investment and program incubation.

Protheragen Inc.